These in vivo results suggests that the tumorigenic phenotype in ovarian cancer cells may vary depending on the level of expression of TIMP-2; it can be provoked and aggravated by a pronounced deficiency of TIMP-2 expression, as shown in gRNA1 cells. This evidence concerns the gene TIMP2 and ovarian cancer.